NeuroPace Cuts Sales Outlook To $91 Million–$92 Million As Major Accounts Stumble
Lower spending narrowed the quarterly loss, but NeuroPace now expects a larger adjusted EBITDA loss for the year.
NeuroPace, which makes a brain implant that monitors activity and delivers electrical pulses to prevent seizures, cut its 2026 sales outlook Thursday to $91 million–$92 million from $99.5 million–$101.5 million. Its earnings release, accompanying an SEC filing, tied the shortfall to problems at major accounts and greater-than-expected disruption from sales-team changes.
Account Problems Reset Growth Expectations
President and CEO Joel Becker said the weakness centered on several of NeuroPace's largest accounts. He said the company is tackling those problems, and “fourth-quarter scheduled cases have begun to recover.”
The revised outlook assumes underlying RNS revenue growth of 10%–11% and approximately $1 million of service revenue. Third-quarter revenue fell 1.1% to $23.1 million from $23.4 million a year earlier, while RNS sales rose 1.4% to $22.9 million.
RNS sales were $21.7 million in the first quarter and $22.5 million in the second. The system treats U.S. adults whose focal epilepsy—seizures originating in a specific brain area—is not controlled by medication. NeuroPace sells initial implants and replacements through a direct sales team focused on epilepsy specialists and neurosurgeons.
Spending Cuts Narrow The Quarterly Loss
NeuroPace's continuing operations lost $3.3 million, or $0.10 a share, compared with $4.9 million, or $0.15 a share, a year earlier. The first and second quarters produced continuing net losses of $6.7 million and $6.2 million, respectively.
Adjusted quarterly operating expenses fell to $19.2 million from $20.7 million. Adjusted gross margin increased to 84.8% from 82.8%, which the company attributed to better absorption of labor costs. Adjusted EBITDA—a measure excluding interest, taxes and certain costs—turned positive at $0.4 million, versus a $1.3 million loss.
Management lowered its annual adjusted operating-expense forecast to $85 million–$86 million from $90 million–$92 million, excluding approximately $10 million of non-cash stock pay. It raised its adjusted gross-margin outlook to 83.0%–83.5% from 82.0%–83.0%.
Even with lower planned spending, NeuroPace now expects an annual adjusted EBITDA loss of $8.5 million–$9.5 million, versus $7.5 million–$8.5 million previously. At September 30, cash, investments and restricted cash totaled $49.5 million, down from $51.9 million at the prior quarter-end; long-term borrowings were $59.2 million.
Remote Programming And Broader Treatment
NeuroPace submitted Remote Care for FDA review, with a planned 180-day review cycle. The proposed feature would let physicians program RNS devices through telehealth, reducing in-person visits and travel barriers for patients far from epilepsy centers.
The company is also seeking approval for idiopathic generalized epilepsy. An October FDA meeting supplied feedback that NeuroPace plans to incorporate into an application amendment expected around year-end.
Enrollment has begun in AURORA, its real-world evidence study supporting potential treatment expansion to adolescents aged 12–17 with drug-resistant focal epilepsy. NeuroPace expects data collection to finish in early 2027, followed by analysis and an FDA submission.
The next planned regulatory step is the generalized-epilepsy application amendment around year-end, while the revised sales outlook still assumes 10%–11% underlying RNS growth.